Initial clinical response predicts outcome and is associated with dose schedule in metastatic melanoma and renal cell carcinoma patients treated with high-dose interleukin 2

Kathryn Spanknebel, Kenneth Y. Cheung, John Stoutenburg, Karl Hurst-Wicker, Charles Hesdorffer, Gail DeRaffele, Howard L. Kaufman

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Fingerprint

Dive into the research topics of 'Initial clinical response predicts outcome and is associated with dose schedule in metastatic melanoma and renal cell carcinoma patients treated with high-dose interleukin 2'. Together they form a unique fingerprint.

Medicine & Life Sciences